Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 14/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | HRH2 | P25021 | 13/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096906 | 0.89 | HRH1 (0.46) | HRH1HTR1ADRD4HTR2AOPRM1 | |
| SCHEMBL6093051 | 0.89 | HRH1 (0.49) | HRH1HTR1ADRD4HTR2AOPRM1 | |
| SCHEMBL5965664 | 0.87 | HRH1 (0.38) | HRH1HTR1ADRD4HTR2AOPRM1 | |
| SCHEMBL6094981 | 0.86 | HRH2 (0.49) | HRH1HRH2HRH3MEN1 | |
| SCHEMBL6201460 | 0.85 | HRH1 (0.48) | HRH1HTR1ADRD4HTR2AOPRM1 | |
| SCHEMBL6095414 | 0.85 | HRH1 (0.40) | HRH1HTR1ADRD4HTR2AOPRM1 | |
| SCHEMBL6093983 | 0.85 | ADAM17 (0.40) | HRH1HTR1ADRD4HTR2AOPRM1 | |
| SCHEMBL6095096 | 0.84 | EPHX2 (0.46) | HRH1HTR1ADRD4HTR2AOPRM1 | |
| SCHEMBL6096867 | 0.83 | HRH1 (0.51) | HRH1HTR1ADRD4HTR2AOPRM1 | |
| SCHEMBL6094069 | 0.83 | GPR119 (0.43) | HRH1HRH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1360187-A1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002060902-A1 | 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | HRH1 2707/4885HTR1A 1544/4885DRD4 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.